NCT06674148View on ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Qifangfeixian Granules in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

October 25, 2024

Primary Completion Date

May 20, 2027

Study Completion Date

June 1, 2027

Conditions

Interstitial Lung DiseaseQifangfeixian Granules

Interventions

DRUG

Qifangfeixian granules

The experimental group was treated with Qifangfixian granules

OTHER

Placebo

The control group was treated with placebo

Trial Locations (1)

430030

RECRUITING

Tongji hospital affiliated to huazhong university of science and technology, Wuhan

All Listed Sponsors

lead

Huilan Zhang

OTHER

NCT06674148 - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Qifangfeixian Granules in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD) | Biotech Hunter | Biotech Hunter